News | July 09, 2009

Hospital Care for Heart Attack, Heart Failure Varies Across Nation

July 9, 2009 – The 30-day mortality and readmission rates for acute care of heart attack and heart failure patients vary significantly from hospital to hospital across the nation, according to a new study published in a current issue of Circulation, the journal of the American Heart Association.

In the article “Cardiovascular Quality and Outcomes,” researchers analyzed findings from the 2009 Centers for Medicare and Medicaid Services (CMS) 30-day outcomes report for acute myocardial infarction and heart failure, part of the CMS Hospital Compare quality initiative.

Researchers reviewed three years of experience (July 2005 to June 2008) of Medicare fee-for-service patients with heart failure and heart attack. Calculating 30-day death and readmission rates, based on nearly 600,000 heart attack admissions and more than 1 million heart failure admissions at almost 5,000 hospitals nationwide, they found:

• The average 30-day death rate for heart attack was 16.6 percent.

• The average rate of heart attack readmission was 19.9 percent.

• The average 30-day death rate for heart failure was 11.1 percent and 24.4 percent for readmission.

The researchers said their findings represent an opportunity for improvement.

"If we just look at readmission, one in four patients who has heart failure and one in five who has a heart attack is back in the hospital within 30 days for readmission," said Harlan M. Krumholz, M.D., the study's lead author, professor of medicine and outcomes researcher at Yale University School of Medicine in New Haven, Conn. "Variations in those rates from hospital to hospital tell yet another story. What we're seeing is that, for example, for heart attack patients, the best hospital in the country has a 30-day mortality rate of only about 11 percent and the hospital with the highest rate in the country has a rate of almost 25 percent."

Researchers also found the heart failure death rate ranged from 6.6 percent to 19.8 percent. Readmission for heart attack ranged from 15.3 percent to 29.4 percent. Readmission for heart failure ranged from 15.9 percent to 34.4 percent.

"This suggests that patients' outcomes are dependent, at least in part, on the hospital that provides their care," Dr. Krumholz said. "What we seem to have here are differences among hospitals that are based on quality and the systems that they have in place. If we could better understand how the best hospitals achieve their results and help the hospitals that are not doing as well improve, we could save many more lives."

He said the release and analysis of the CMS data may now make that possible.

"The hope is that this information will stimulate constructive engagement by the healthcare community to find ways to improve performance and patient outcomes," he said.

The U.S. Centers for Medicare & Medicaid Services funded the study.

For more information: www.americanheart.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init